Episodic, or bundled payments, is a concept now
familiar to most in the healthcare arena, but the models are often
misunderstood. Under a traditional fee-for-service model, each provider
bills separately for their services which creates financial incentives
to maximise volumes. Under a bundled payment, a single entity, often
referred to as a convener (maybe the hospital, the physician group,
or a third party) assumes the risk through a payer contract for
all services provided within a defined episode of care, and receives
a single (bundled) payment for all services provided for that episode.
The time frame around the intervention is variable, but defined
in advance, as are included and excluded costs. Timing of the actual payment
in a bundle may either be before the episode occurs (prospective
payment model), or after the end of the episode through a reconciliation
(retrospective payment model). In either case, the defined costs
over the defined time frame are borne by the convener. Cite this article:
Antibiotic resistance represents a threat to human health. It has been suggested that by 2050, antibiotic-resistant infections could cause ten million deaths each year. In orthopaedics, many patients undergoing surgery suffer from complications resulting from implant-associated infection. In these circumstances secondary surgery is usually required and chronic and/or relapsing disease may ensue. The development of effective treatments for antibiotic-resistant infections is needed. Recent evidence shows that bacteriophage (phages; viruses that infect bacteria) therapy may represent a viable and successful solution. In this review, a brief description of bone and joint infection and the nature of bacteriophages is presented, as well as a summary of our current knowledge on the use of bacteriophages in the treatment of bacterial infections. We present contemporary published in vitro and in vivo data as well as data from clinical trials, as they relate to bone and joint infections. We discuss the potential use of bacteriophage therapy in orthopaedic infections. This area of research is beginning to reveal successful results, but mostly in nonorthopaedic fields. We believe that bacteriophage therapy has potential therapeutic value for implant-associated infections in orthopaedics. Cite this article:
